Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.

Abstract

During the past several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept.

• Authors: Jeffrey M Weinberg, William D Tutrone
• Journal: Cutis (Cutis) Vol. 71 Issue 1 Pg. 41-5 (Jan 2003) ISSN: 0011-4162 [Print] United States
• PMID: 12553629 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Recombinant Fusion Proteins
• Alefacept
• efalizumab

Topics

• Alefacept
• Antibodies, Monoclonal (administration & dosage, pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Biological Therapy
• Drug Delivery Systems
• Humans
• Psoriasis (drug therapy)
• Recombinant Fusion Proteins (administration & dosage, pharmacology, therapeutic use)
• T-Lymphocytes (drug effects)